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 Abstract. In case of pets, dogs and cats transfusions are already a current practice, beeing an 
intensive therapy procedure. In a group of dogs that underwent intensive therapy hole blood 
transfusion was used based on major and minor Crossmatch test results in order to establishing blood 
compatibility. The slide and tube techniques used were original and taken from different authors. 
Using 15 potential donors, 5 patients were transfused, one of them diagnosed with osteosarcoma. In 4 
of the patients, all donor tested were compatible and they recovered after blood transfusion. 
Incompatibility problems appeared in the patient with osteosarcoma, for which 11 potential donors 
were tested and among them only 2 were compatible, the others showed positive agglutination 
reaction in major crossmatch In patients with positive reactions of incompatibility, the results were 
relevant in both variants (slide, tube), meaning the high level of plasmatic alloantibodies. After the 
evaluation of blood compatibility using major and minor crossmatch tests it was decided to opt for 
blood transfusion which made possible the recovery of 4 out of 5 dogs undergoing intensive therapy. 
The development was fatal for the patient with osteosarcoma because of the severe complications 
caused by the cancer. The highly positive major crossmatch results obtained in the patient with 
osteosarcoma and 9 potential donors, who never received a transfusion, suggest the possibility of 
producing alloantibodies to some foreign cancer induced proteins, cross-reactant with common 
erythrocyte antigens. 
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INTRODUCTION 
 
Establishing the blood transfusion compatibility in dogs can be done by using 
crossmatch testing alone or in addition to blood typing of the donor and receiver. There are 
cases when the crossmatch test can be sufficient for a safe transfusion therapy while in other 
cases blood typing is necessary. 
The large diversity of the erythrocytes antigenic profiles is characterized by the fact 
that dogs do not have naturally occurring antibodies to the 13 clinically significant erythrocyte 
antigens, as we can see in cats and other species. (Giger and col, 2005) 
It is notable that the crossmatch tests only the presence or the absence of the plasmatic 
anti-erythrocytes antibodies in the tested partners (Giger and Blais, 2005) and for this reason 
doesn’t exclude the possibility of the immunogenic transfusion reaction, so-called febrile non-
hemolytic transfusion reactions, generated by the leukocyte/platelet. 
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MATERIALS AND METHODS 
 
For the evaluation of the blood transfusion compatibility and detection of the anti-
erythrocyte alloantibodies present in the donor or recipient plasma we resorted to determining 
the relevance of agglutination and hemolysis reactions, using different variants of crossmatch. 
Five patients subjected to intensive therapy procedures, who also needed blood 
transfusions, were tested before transfusion. Three of them were mixed breeds, one was a 
Siberian husky and the other Rotweiller. 4 patients were compatible with the first tested 
donors, but the 5-th patient, a Rotweiller male, diagnosed with left scapular osteosarcoma, and 
needed more tests. 
The patients were suffering of progressive states of anemia (a total number of 
erythrocytes under 5 mil/ml of blood) and after clinical and hematological evaluation (18 
parameters determined with automatic analyzer-Abacus junior vet) we opted for transfusion 
therapy. Worsening trends in the patient with osteosarcoma required completing the 
haematological investigations with biochemical and immunological tests ( plasmatic level of 
IgG and IgM). 
The group of potential donors included 15 healthy dogs, vaccinated and parasite free; 
from different breeds and ages (between 5 months to 10 years).We also tested, as a potential 
donor, a dog with lymphoma, to distinguish the likelihood of incompatibility reactions 
generated by the development of cancer. None of the tested dog had been transfused with 
blood products. Among the tested potential donors there were 3 females that had one or more 
series of puppies. 
The methods for testing the transfusion compatibility included different techniques of 
major and minor crossmatch. Some of them were based on adaptations of crossmatch 
techniques from reference literature and the others were based on the elaboration of original 
methods on slide and in tube rapid tests. The tests were performed between patients and 
potential donors and also between donors. The autoagglutination was checked in the same 
time in every dog 
 The majority of samples, needed for testing and the obtaining of plasma, were 
collected on EDTA, beside these, for some we used citrate/oxalate. The serums were obtained 
from samples collected in tubes containing clotting activator.  
 Following the work protocol, first of all we began with a rapid slide test variant, 
elaborated by us. This consist of: the mixture of 3 µl donor erythrocyte concentrate with 12µl 
plasma/serum from the recipient, in the case of major crossmatch, in the case of the minor 
crossmatch, the same quantities from recipient erythrocyte with donor plasma/serum. The 
autoagglutination control was done using reagents from the same dog, mixing the above 
mentioned quantities of erythrocytes with plasma/serum. 
 The macro agglutination was interpreted after slow rotation movements of the slide 
and the micro agglutination was checked at microscope with 10X. 
For the patient with osteosarcoma we also proceeded to a test variant for erythrocytes 
using human blood group Hemotests. The procedure consists in checking the slide 
agglutination of the tested erythrocytes with antiA, antiB and antiD serums. (Ognean  and 
col.,2008) 
Nine positive results, represented by slide agglutination, were noticed only in case of 
the patient with osteosarcoma, who was also tested using tube methods as we describe below. 
Tube test crossmatch, after Bernard F.Feldman 2006, with the following steps: 
• Preparation of the erythrocyte suspension from donor and recipient by placing 0,2 ml 
of erythrocyte in 4,8 ml normal saline; 
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• Preparation of the plasma/serum from the two partners using known methods (Ognean 
and col, 2008) 
• Testing major crossmatch by mixing, in three small test tubes, 0,1 ml donors 
erythrocyte suspension with 0,1 ml recipient serum/plasma; 
• Testing minor crossmatch by using the same quantities of recipient erythrocytes and 
donor plasma/serum; 
• Incubation of the samples, for 15 minutes at 3 various temperatures: 37oC, 4oC and 
room temperature; 
• Reading results, after a preliminary centrifugation for 1 minute at 3500rpm – 
examination of the supernatant for any hemolysis, slowly shake to observe the 
presence of agglutination, like a compact mass or small parts of this; 
• Performing the control test for the autoagglutination using the plasma and erythrocytes 
from the same dog in the above mentioned technique and quantities; 
Modified Crossmatch tube test presented by Dodds, W. Jean at the 30th World Small Animal 
Veterinary Association World Congress,Mexico, 2005. After the adaptation of this test the 
following stages have resulted: 
• Preparation of red blood concentrate ( pRBC), plasma and blood serum, using the 
usual techniques; 
• Washing donor and recipient pRBC: in two small tubes test add one drop of pRBC 
and 2 ml saline, spin at 2500 rpm, pour off saline, add fresh saline and spin as before. 
Repeat 3 times, leaving cells in tubes; 
• Major crossmatch:-add two drops of recipient plasma to washed donor RBC; 
• Minor crossmatch-add two drops of donor plasma to washed recipient RBC; 
• Autoagglutination control using reagents from the same dog in the quantities 
mentioned above. Both controls should be negative; 
• Checking the results on slide-mix tubes, place one drop from each tube on separate 
microscope slides to check for agglutination or haemolysis; 
Tube test crossmatch : 
• Major crossmatch: adding of a drop from donor pRBC in a small test tube to a drop of 
recipient plasma/serum and then fill the tube with saline 
• Minor crossmatch:mix recipient pRBC with donor plasma as before 
• After 5 minutes at room temperature centrifuge the tubes 3 min at 3500rpm 
• Reading of the results: like we previously mentioned. 
 
RESULTS AND DISCUSSION 
 
In 9 cases we obtained positive results in major crossmatch test, using slide technique, 
and these were represented by agglutination. Minor crossmatch tests were all negative. The 
agglutination intensity varied from + to ++++ (Tab1). 
It is also mentionable that in all cases positive agglutination results were expressed 
very clear in t macroscopic and microscopic examination of the slides (Fig1,2) 
Crossmatch tests performed in tube showed similar results, but the incubation at 37oC 
of the samples provided a clearer expression of the intensity of agglutination reactions, and a 
differentiation based on color, of the haemolysis. 
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Table 1. 
The evolution of the agglutination intensity reaction in crossmatch compatibility tests 
TEST 
(no.) DONOR RECIPIENT 
MAJOR 
CROSSMATCH  
MINOR 
CROSSMATCH 
 
1 Rotweiller +++ - 
2 Romanian Shepherd ++ - 
3 Mixed breed ++++ - 
4 Labrador retriever ++ - 
5 GermanShepherd - - 
6 Mixed breed +++ - 
7 German Shepherd +++ - 
8 German Shepherd - - 
9 Mixed breed ++++ - 
10 Fox terrier +++ - 
11 Mixed breed 
Patient  
(Rotweiller with 
osteosarcoma) 
++++  
12 Rotweiller (1) Romanian Shepherd (2) - - 
13 Mixed breed (3) Labrador retriever (4) - - 
14 Fox terrier (10) Mixed breed (9) ++++ - 
 
                      
Fig.1.Macroscopic agglutination                           Fig.2. Microscopic agglutination 
 
All minor crossmatch tests showed negative reactions in the tube, like on slide. All 
incompatibilities were detected between the patient with osteosarcoma and 9 of the 11 donors 
tested. In this dog the serum titre of immunoglobulins has exceeded the physiological limits 
(IgG-2017mg/dl and IgM-408 mg/dl) and the biochemical changes consisted in increased 
alkaline phosphatase (640U / L), ASAT(141 U / L), creatinine (5.6 mg / dl) and blood glucose 
(541 g/dl). 
Note also the appearance of incompatibility between this patient with osteosarcoma and a 
donor with limphoma.  
Only 2 potential donors were compatible with this patient with osteosarcoma, both being 
German shepherd dogs. 
The major Crossmatch test results between donors showed the incompatibility only in 
one case ,for dog with lymphoma ,the agglutination intensity was assessed + + +. 
On the basis of negative results recorded in all performed autoagglutination tests, the 
evolution of autoimmune hemolytic anemia in these dogs was excluded. 
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The tests with anti-human erythrocyte antigens we obtained negative reactions, which 
could exclude dogs belonging to group test DEA 7.Regarding this, Bowdler and col., implies 
the existence of a similarity between the Tr antigen (DEA7) and the A antigen from human 
red blood cells. ( Bull and Slating, 1971) 
According to the obtained results, detecting elevated levels of canine anti-erythrocyte 
alloantibody can also be done on with the use of major Crossmatch slide techniques which 
can be as relevant as the tube methods. 
As most researchers in the field have found, the crossmatch test is absolutely 
necessary to verify the pretransfusion compatibility in dogs that have received a previous 
blood transfusion and females that have had puppies. 
Starting from the fact that there are no known specific natural aloantibodies which 
cause important posttransfusion reactions, there are authors who consider that the first blood 
transfusion should not create problems. (Slatter, 2003) Moreover, some of them consider that 
crossmatch test may be omitted in practice before the first transfusion .(Giger and Blais, 
2005) 
Although in our study no dog has received blood transfusion, we observed a number 
of 9 agglutination, some of them having a very strong intensity. In case of the dog suffering 
from osteosarcoma we can assume the formation of antibodies against some cancer induced 
foreign proteins, which give cross-reactions with the erythrocytes of other healthy dogs. For 
this reason we resorted to testing another patient with cancer, respectively lymphoma, after 
which we obtained similar results to the first case. This may support the hypothesis that some 
plasmatic alloantibodies found in dogs with cancer can agglutinate canine red blood cells. To 
better support such findings, the plasma from lymphoma patient should also agglutinate the 
erythrocytes from osteosarcoma patient and obtaining a positive minor crossmatch. 
As we mentioned, obtaining an incompatible major crossmatch test reveals the 
destruction of the transfused erythrocytes by the plasmatic antibodies and this can result in 
very severe consequences for the patient being transfused.(Giger and Blais, 2005)Such 
incompatibilities are included in the mechanism of the type 2 hypersensitivity reaction 
(antigen-antibody). 
Aloantibodies involved in the positive crossmatch reactions are hemolysins or 
haemagglutinins and can be directed against antigens of known blood type or other antigens 
on the surface of erythrocytes. (Giger and Blais, 2005) 
Giger and col. also mentions that in patients with a very low hematocrit (below 10%) 
the crossmatch test cannot highlight a possible positive response to incompatibility. 
According to the same author, major crosmatch test also give errors in the event of 
autoagglutination, when it’s recommended the use of washed (at least 3 times) red blood cells. 
In this context, is estimated that in cases of autoagglutination intensity reactions from + to 
++++, the patient will receive only DEA1 negative blood until the disappearance of the 
autoagglutination and then repetition the crossmatch test. 
Our results also reveal an important fact in testing the hemotransfusion compatibility 
of patients with cancer, recommending crossmatch test even before the first transfusion. We 
also mention that crossmatch test do not replaces blood typing and doesn’t exclude a possible 
sensitization of the recipient. 
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CONCLUSIONS 
Blood compatibility testing with different crossmatch techniques in a group of dogs that 
underwent intensive therapy was the basis for the following conclusions: 
1. Major Crossmatch slide techniques may be as relevant as those in tube, for the 
detection of elevated alloantibodies levels in dogs, the use of blood typing is needed 
for a more complex assessments of compatibility; 
2. Increased frequency of negative results to major Crossmatch tests confirm the lack of 
preformed plasmatic alloantibodies in most tested cases, because they have not gone 
through any previous form of hemotherapy; 
3. Assessing the compatibility using Crossmatch tests has made possible the transfusion 
of whole blood, with recovery of 4 of the 5 dogs underwent intensive therapy, the 
evolution being fatal for the patient with ostosarcoma, because of severe 
complications caused by cancer; 
4. Getting positive reactions to major Crossmatch tests confirms once again the 
possibility of posttransfusion alloantibodies formation in dogs, even if initial tests 
were consistent with several donors. In this case a reliable source of compatible blood 
remaining the whelps. 
5. First blood transfusion in dog should not create compatibility issues, although there 
may be cases with high levels of natural antibodies, detected by major Crossmatch 
test. The test is recommended for all patients who have already undergone a blood 
transfusion and in females who have had puppies. 
6. Intense positive reactions of major Crossmatch tests found in the patient with 
osteosarcoma and the 9 potential donors, without any of these having underwent any 
blood transfusions, suggests the possibility of antibodies formation, similar to blood 
group isoaglutinins, to certain foreign proteins induced by cancer; 
7. Agglutination of the lymphoma dog erythrocytes with osteosarcoma dog plasma, but 
not vice versa, reveals the need for compatibility testing of all patients with cancer 
undergoing transfusion therapy with blood products. 
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